scholarly journals Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development

Pathogens ◽  
2020 ◽  
Vol 9 (2) ◽  
pp. 148 ◽  
Author(s):  
Balamurugan Shanmugaraj ◽  
Ashwini Malla ◽  
Waranyoo Phoolcharoen

Novel Coronavirus (2019-nCoV) is an emerging pathogen that was first identified in Wuhan, China in late December 2019. This virus is responsible for the ongoing outbreak that causes severe respiratory illness and pneumonia-like infection in humans. Due to the increasing number of cases in China and outside China, the WHO declared coronavirus as a global health emergency. Nearly 35,000 cases were reported and at least 24 other countries or territories have reported coronavirus cases as early on as February. Inter-human transmission was reported in a few countries, including the United States. Neither an effective anti-viral nor a vaccine is currently available to treat this infection. As the virus is a newly emerging pathogen, many questions remain unanswered regarding the virus’s reservoirs, pathogenesis, transmissibility, and much more is unknown. The collaborative efforts of researchers are needed to fill the knowledge gaps about this new virus, to develop the proper diagnostic tools, and effective treatment to combat this infection. Recent advancements in plant biotechnology proved that plants have the ability to produce vaccines or biopharmaceuticals rapidly in a short time. In this review, the outbreak of 2019-nCoV in China, the need for rapid vaccine development, and the potential of a plant system for biopharmaceutical development are discussed.


2021 ◽  
Vol 10 (2) ◽  
pp. 01-05
Author(s):  
Augustine Owusu-Addo ◽  
Atianashie Miracle A ◽  
Chukwuma Chinaza Adaobi ◽  
Larissa Agbemelo-Tsomafo

COVID-19, also known as the ‘novel coronavirus disease 2019’, is a respiratory illness and the causative pathogen is officially named as ‘SARS-CoV-2’. Infections with SARS-CoV-2 have now been amplified to a global pandemic – as of April 3, 2020, nearly 1,018,000 cases have been confirmed in more than 195 countries, including more than 300,000 cases within the United States. Public safety guidelines are followed worldwide to stop the spread of COVID-19 and stay healthy. Despite COVID-19 is a respiratory illness with mode of invasion through the respiratory tract, not the gastrointestinal tract, an average food consumer is anxious and concerned about the food safety. Could an individual catch the deadly contagious COVID-19 from groceries brought home from the supermarket – or from the next restaurant takeout order? This brief review elucidates the epidemiology and pathobiological mechanism(s) of SARS-CoV-2 and its implications in food-borne infections, transmission via food surfaces, food processing and food handling.



1998 ◽  
Vol 9 (5) ◽  
pp. 319-321 ◽  
Author(s):  
Bonita E Lee ◽  
Ari R Joffe ◽  
Wendy Vaudry

Hantavirus pulmonary syndrome (HPS) was first recognized as a severe respiratory illness transmitted through rodent excreta in the southwestern United States in 1993. As of November 1997, 175 cases have been reported in the United States. The mortality rate of this disease has been reported to be as high as 52% in the United States, and the majority of the cases (94%) involved adults. Twenty-one cases have been recognized in Canada. This paper describes the first Canadian paediatric case and discusses some of the clinical features of this disease.



Author(s):  
Usman M Ashraf ◽  
Ahmed A Abokor ◽  
Jonnelle M. Edwards ◽  
Emily W. Waigi ◽  
Rachel S. Royfman ◽  
...  

A novel coronavirus disease, COVID-19, has created a global pandemic in 2020, posing an enormous challenge to healthcare systems and affected communities. COVID-19 is caused by Severe Acute Respiratory Syndrome (SARS)-CoronaVirus-2 (CoV-2) that manifests as bronchitis, pneumonia, or a severe respiratory illness. SARS-CoV-2 infects human cells via binding a "spike" protein on its surface to angiotensin-converting enzyme 2 (ACE2) within the host. ACE2 is crucial for maintaining tissue homeostasis and negatively regulates the renin-angiotensin-aldosterone system (RAAS) in the humans. The RAAS is paramount for normal function in multiple organ systems including the lungs, heart, kidney, and vasculature. Given that SARS-CoV-2 internalizes via ACE2, the resultant disruption in ACE2 expression can lead to altered tissue function and exacerbate chronic diseases. The widespread distribution and expression of ACE2 across multiple organs is critical to our understanding of the varied clinical outcomes of COVID-19. This perspective review based on the current literature was prompted to show how disruption of ACE2 by SARS-CoV-2 can affect different organ systems.



2020 ◽  
Vol 73 (7) ◽  
pp. 366-369 ◽  
Author(s):  
Tahir S Pillay

The year 2020 has seen a major and sustained outbreak of a novel betacoronavirus (severe acute respiratory syndrome (SARS)-coronavirus (CoV)-2) infection that causes fever, severe respiratory illness and pneumonia, a disease called COVID-19. At the time of writing, the death toll was greater than 120 000 worldwide with more than 2 million documented infections. The genome of the CoV encodes a number of structural proteins that facilitate cellular entry and assembly of virions, of which the spike protein S appears to be critical for cellular entry. The spike protein guides the virus to attach to the host cell. The spike protein contains a receptor-binding domain (RBD), a fusion domain and a transmembrane domain. The RBD of spike protein S binds to Angiotensin Converting Enzyme 2 (ACE2) to initiate cellular entry. The spike protein of SARS-CoV-2 shows more than 90% amino acid similarity to the pangolin and bat CoVs and these also use ACE2 as a receptor. Binding of the spike protein to ACE2 exposes the cleavage sites to cellular proteases. Cleavage of the spike protein by transmembrane protease serine 2 and other cellular proteases initiates fusion and endocytosis. The spike protein contains an addition furin cleavage site that may allow it to be ‘preactivated’ and highly infectious after replication. The fundamental role of the spike protein in infectivity suggests that it is an important target for vaccine development, blocking therapy with antibodies and diagnostic antigen-based tests. This review briefly outlines the structure and function of the 2019 novel CoV/SARS-CoV-2 spike protein S.



2020 ◽  
Author(s):  
Theresa Marie Bernardo ◽  
Kurtis Edward Sobkowich ◽  
Russell Othmer Forrest ◽  
Luke Stewart ◽  
Marcelo D'Agostino ◽  
...  

UNSTRUCTURED Introduction: The emergence of COVID-19 spurred the formation of myriad teams to tackle every conceivable aspect of the virus and thwart its spread. Collaboration has become a constant theme throughout the 2019 novel coronavirus pandemic and has resulted in expedition of the scientific process (including vaccine development), rapid consolidation of global outbreak data and statistics, as well as experimentation with novel partnerships. Enabling these collaborative efforts is a state of global connectedness where data travels between countries in fractions of a second, allowing for partnerships and information sharing to occur virtually, with no need for physical proximity or even prior knowledge of your collaborators. The objective of this article is to document the evolution of these collaborative efforts, using illustrative examples collected by the authors throughout the pandemic and supplemented with publications from the JMIR COVID-19 Special Issue on coronavirus. Main Themes: Over 60 projects rooted in collaboration are categorized into five main themes: knowledge dissemination; data propagation; crowdsourcing; artificial intelligence; and hardware design and development. They highlight the numerous ways that citizens, industry professionals, researchers, and academics have come together globally to consolidate information and produce products geared towards combating the COVID-19 pandemic. With the overwhelming quantity of information, it can be challenging to gauge quality and detect misinformation, which is exacerbated by the inability to rapidly collect and share robust public health data. Initially, researchers and citizen scientists scrambled to pull together any accessible data. As global curated data sets started to emerge, numerous derivative works, such as visualizations or models, were developed that depended on the consistency of that data and which would fail when there were unanticipated changes. Crowdsourcing was used to collect and analyze data, aid in contact tracing, and to produce personal protective equipment (PPE) by sharing open designs for 3D printing. National and international consortia of entrepreneurs collaborated with researchers, including a Nobel Laureate, to create a ventilator that received rapid government approval and which was based on an open-source design. An equally impressive coalition of NGOs and governmental organizations led by the White House Office of Science and Technology Policy created a shared open resource of over 200,000 research publications about COVID-19 and subsequently challenged experts in artificial intelligence to answer 17 key questions, offering cash prizes for the best solutions. Conclusions: A thread of collaboration weaved throughout the pandemic response, which represents more than a series of random events. Thrust upon us, it will shape future efforts, pandemic or non-pandemic related. Novel partnerships, combining citizens, entrepreneurs, small businesses, corporations, academia, and governmental and non-governmental organizations will cross boundaries to create new processes, products and better solutions to consequential societal challenges.



2020 ◽  
Vol 2 (2) ◽  
pp. 110-123
Author(s):  
Kulvinder Kochar Kaur ◽  
◽  
Gautam Allahbadia ◽  
Mandeep Singh ◽  
◽  
...  

Since the outbreak of the novel Coronavirus in December 2019 in Wuhan China, this novel Coronavirus disease(COVID-19) has spread worldwide taking not only epidemic proportions but with its rapid spread world health organization(WHO) was forced to declare it as a pandemic. The Severe Acute respiratory syndrome (SARS)-Coronavirus (CoV2) virus is responsible for clusters of severe respiratory illness that simulates acute respiratory syndrome that was what was initially. It is thought although that it is equivalent to the high altitude pulmonary oedema (HAPE), showing glass ground opacities in lungs. More experience is getting acquired with changes in treatment approaches from PEEP to avoid intubation and just ensure oxygen levels maintained. Human to human transmission through droplets, contaminated hands as well as surfaces, has been revealed with an incubation period varying from 2-14 days. Early diagnosis using reverse transcription polymerase chain reaction (RT-PCR) or computed tomography (CT) scan chest, quarantine, as well as supportive treatment are necessary for getting a cure. In this review we have tried to analyze the epidemiology, diagnosis, isolation, and treatment, including antiviral drugs like remdesivir, favipiravir, chloroquine and hydroxychloroquine, corticosteroids, antibiotics, and ivermectin. With 3 successful cases of convalescent plasma achieved in USA, trials going on in India along with vaccines are also detailed in this article.



Author(s):  
Yongchang Xu ◽  
Leyi Wang ◽  
Xu Jia ◽  
Youjun Feng

A novel coronavirus (2019-nCoV) that is initially found to trigger human severe respiratory illness in Wuhan City of China, 2019, has been recognized as a public health emergency of international concern. In the past two months, this deadly agent has caused 77,785 cases with 2,666 deaths via rapid person-to-person transmission and reached at least 25 countries. However, its evolutionary origin is poorly understood. Here we show integrative evidence that 2019-nCoV is a possible progenitor for SARS-CoV with bat origin. Our finding underscores the importance of tracing origin in the efficient monitoring, and effectively preventing the interspecies transmission of such emerging/re-emerging coronaviruses.



2012 ◽  
Vol 17 (40) ◽  
Author(s):  
A Bermingham ◽  
M A Chand ◽  
C S Brown ◽  
E Aarons ◽  
C Tong ◽  
...  

Coronaviruses have the potential to cause severe transmissible human disease, as demonstrated by the severe acute respiratory syndrome (SARS) outbreak of 2003. We describe here the clinical and virological features of a novel coronavirus infection causing severe respiratory illness in a patient transferred to London, United Kingdom, from the Gulf region of the Middle East.



Sign in / Sign up

Export Citation Format

Share Document